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1. Introduction
Oral and maxillofacial tissues are a complex array of bone, cartilage, soft tissue, nerves and
vasculature. Damage to these structures, even when minimal, usually leads to noticeable
deformities. Therefore, the repair of large segmental bone defects of the jaw or mandible due
to trauma, inflammation, or tumor surgery remains a major clinical problem. For many years,
simple autogenic, allogenic, or xenogenic bone grafts, or combinations thereof, have been the
mainstay for tissue replacement [1]. However, when large bone defects are present, advanced
approaches such as free tissue transfer with microvascular reanastomosis of vascularized flaps
from distant sites including the fibula, iliac crest, scapula, and radius are needed to repair or
regenerate a functionally complex tissue such as maxillofacial tissue [2, 3]. While these
procedures have proven to be reliable and effective, they require extended hospitalization, and
a secondary donor site with the associated morbidity and complications. As an alternative to
current surgical techniques or approaches, developments in tissue engineering using the gene
therapy and stem cell biology strive to utilize cells, biomaterial scaffolds and cell signaling
factors to regenerate large oral and maxillofacial tissues defect with precise replication of
normal body contours. A tissue engineering approach offers several potential benefits,
including a decrease in donor site morbidity, a decrease in technical sensitivity of the repair,
and the ability to closely mimic the in vivo microenvironment in an attempt to recapitulate
normal craniofacial development [1].
Mesenchymal stem cells (MSCs) derived from bone marrow have been used experimentally
for tissue engineering applications [4-6]. MSCs can differentiate into several different cell types,
such as those that produce bone, cartilage, tendon, and other connective tissues, as well as
muscle, adipose, and dermal cells [7-10]. MSCs can be expanded in culture while maintaining
their multipotency.
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The concept of prefabricated bone engineering with MSCs for large bone defects may play a
pivotal role in future therapies. However, bone marrow-derived MSCs have been reported to
require selective sera lots and growth factor supplements for culture expansion [11]. Further‐
more, traditional bone marrow procurement, particularly in volumes larger than a few
milliliters may be painful, frequently requiring general or spinal anesthesia [12-14].
Bone marrow tissue provides the most universal and attractive source of MSCs; however, other
tissues such as periosteal [15], muscle [16], synovial membrane [17] and adipose [18-20] tissues
also appear to possess MSCs. Particularly, adipose tissue is an important source of stem cells
because subcutaneous adipose tissue is an abundant and accessible source of both uncultured
stromal vascular fraction (SVF) cells and cultured homogeneous adipose-derived stem cells
(ASCs) (21). ASCs obtained from lipoaspirates have multilineage potential and will differen‐
tiate into adipogenic, chondrogenic, myogenic, osteogenic, and neurogenic cells [19, 22, 23].
Thus, ASCs have great potential for clinical applications such as the repair of damaged tissues
and angiogenic therapy. Injection of human ASCs was recently shown to improve neovascu‐
larization in an ischemic hindlimb mouse model and osteoid matrix formation in immunoto‐
lerant mice [24-26]. Further, ASCs have been shown to increase the functional capacity of
damaged skeletal muscle in vivo [27]. Therefore, these reports suggest that ASCs may also
have the potential for use in large bone tissue engineering techniques such as prefabrication.
Recently, prefabricated bone engineered with ASCs was reported both with in vivo studies in
rat and a clinical human case. Thus, the use of ASCs in maxillofacial tissue reconstruction
should be viewed favorably and these novel approaches may have advantages for tissue
reconstruction.
In this chapter, the current approaches and the biomaterials used for repair of large bone
defects are presented, and the novel approach of prefabricated bone engineering with MSCs
and ASCs is introduced.
2. Current therapy for large bone reconstruction
Bone tissue is composed of heterogeneous cell types embedded in a three-dimensional
mineralized extracellular matrix. The scaffolds for repair of large bone defects, including
autogenous bone grafts or biomaterials, must provide the necessary support for cells to
proliferate while maintaining their potential to differentiate, and must possess an architecture
suitable for matching the final shape of the newly formed bone [28].
2.1. Autologous bone reconstruction
The current  standard of  care  for  repair  of  critical  large bone defects  consists  of  autoge‐
nous bone grafting using bone from the rib  or  iliac  crest  of  the patient.  An autologous
bone  graft  is  still  the  ideal  material  for  the  repair  of  craniofacial  defects;  however,  the
availability of autologous bone is limited and harvesting can be associated with complica‐
tions [29]. Vascularized and avascular autogenous bone has a greater osteogenic capacity
than  any  other  bone  replacement  material,  as  revascularization  attracts  mesenchymal
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differentiation  into  osteogenic,  chondrogenic  and  other  cell  types.  Autogenous  bone
transplants possess an inherent biocompatibility and are therefore more easily incorporat‐
ed  without  immunogenic  responses  [30].  However,  the  clinical  use  of  autologous  bone
transplants  is  limited  by  considerable  donor  site  morbidity,  which  increases  with  the
amount  of  harvested bone.  Bleeding,  hematomas,  infections,  and chronic  pain  are  com‐
mon complications of autologous bone graft harvests [31, 32].
2.2. Allogenic/Xenogenic bone reconstruction
Demineralized bone matrix (DMB) is the de-cellularized and organic component of bone, and
is a commercially available osteoinductive and osteoconductive biomaterial. DMB represents
a concentrated source of bone morphogenetic proteins (BMPs) and has been used in numerous
animals systems since its initial description in 1965 [33]. The widespread use of DMB in humans
still remains restricted since the immunologic properties of donor DMB are unknown [34].
With the disadvantages of host morbidity and the limits in suitable harvesting sites and
material for autologous grafts, the use of xenografts might be considered for large bone
reconstructions, although the histocompatibility issues between the human recipient and
animal donor preclude the use of bone xenografts [34]. However, bovine-derived DMB is
currently used in oral and maxillofacial surgery [35].
2.3. Synthetic scaffolds for bone reconstruction
A wide variety of synthetic (alloplastic) scaffolds such as ceramics and polymers are used
clinically for bone grafting [30]. Ceramics are crystalline, inorganic, nonmetallic minerals that
are held together by ionic bonds and usually densified by sintering [36]. Ceramics such as
hydroxyapatite and β-tricalcium phosphate (TCP) are currently in use clinically for bone tissue
regeneration of large bone defects.
Various synthetic polymer scaffolds exhibit different structural, mechanical and degradation
properties that make then suitable for bone tissue engineering [36]. Blending polymers of
different molecular weights can achieve both optimal degradation rates and mechanical
properties [37]. Some synthetic polymer scaffolds such as polycaprolactone (PCL) scaffold,
polylactic acid (PLLA), polyglycolic acid (PGA) and polylactic-co-glycolic acid (PLGA)
materials have been approved by the FDA for craniofacial applications or as absorbable sutures
and bone pins/screws [36].
2.4. Gene therapy for bone reconstruction
The use of exogenous cytokines and growth factors, which are essential for bone regeneration,
promotes cell adhesion, proliferation, migration and osteogenic differentiation [28]. Growth
factors such as BMPs, fibroblast growth factors (FGFs), insulin-like growth factors (IGF),
vascular endothelial growth factors (VEGF) and platelet-derived growth factors (PDGF) have
been used in bone regeneration [28, 36].
Recently the use of combinations of growth factors, such as BMP-2 and NEL-like molecule-1
(NELL-1), was tested in rapid distraction osteogenesis in a rabbit model. The combined
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treatment produced significantly greater bone healing compared to single growth factor
treatments after four weeks of treatment [38]. However, some reports have cautioned that the
clinical use of BMPs and VEGF is in its infancy, and some risks may accompany their use.
VEGF is commonly upregulated in various types of tumors to enhance their vascularization,
and subcutaneous sarcomas were found in some rats administered recombinant human BMP-7
[39, 40], although no clinical relationship has been established between the use of these growth
factors and tumor formation.
2.5. Prefabricated bone engineering for oral and maxillofacial tissue reconstruction
Prefabrication is an interesting area of oral and maxillofacial surgery and plastic and recon‐
structive surgery, because it represents a bridge between conventional reconstructive surgery
and tissue engineering [41, 42]. The purpose of prefabrication is to build a tissue (muscle, bone,
skin, or composite) with characteristics as similar as possible to those of the defect that is to be
repaired [43]. Conventional osteomyocutaneous flaps do not always meet the requirements
for repairing a composite defect. A prefabricated composite flap can be created according to
the complex geometry of the defect. Prefabrication of multi-component flaps is a well estab‐
lished procedure in plastic and reconstructive surgery [41]. This concept is based on the
revascularization phenomenon directly related to host tissue vascularity [44] and has signifi‐
cantly expanded the frontiers of reconstructive surgery.
Hirase et al. were the first to report the use of prefabricated myocutaneous and osteomyocu‐
taneous tissue in a rat model [45]. Flap prefabrication using conventional bone grafts allows
for generation of new types of flaps independent of the vascular anatomy of the bone trans‐
plant. However, the donor site morbidity after harvesting of bone for grafting is still a problem.
Recently, biomaterials, osteogenic cells and osteoinductive growth factors have been used for
generation of vascularized bone tissues in combination with a vascular axis or vascularized
flaps. An inflammatory wound healing response as a reaction to the surgical implantation
induces vascularization of the scaffolds [31]. Induction of axial vascularization protected the
porous biomaterials from bacterial infection and transfer of this vascularized hard tissue as a
free flap has been demonstrated [46]. Prefabricated vascularized bone grafts have been used
in a clinical setting for mandibular reconstruction following thorough in vivo evaluation in a
pig model [47-49]. In these studies, granules of xenogenic bone minerals soaked with recombi‐
nant Osteogenic protein-1 were implanted into the latissimus dorsi muscle and the neo-tissue
was subsequently transferred to sites of mandibular defects using microsurgical techniques.
3. Mesenchymal stem cells for oral and maxillofacial tissue reconstruction
3.1. Mesenchymal stem cells for bone engineering
The bone marrow is not only the site where hematopoiesis occurs in postnatal life, it is also a
reservoir of pluripotent stem cells for mesenchymal tissues [50]. Plated at low densities, single
precursor cells derived from bone marrow, and referred to as colony-forming units, give rise
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to distinct and heterogeneous colonies. These colonies have been shown to undergo osteogenic,
chondrogenic and adipogenic differentiation [51].
Chang and colleagues showed that MSCs can produce ectopic bone generation in a mouse
model [52]. A suspension of osteogenically induced MSCs was added to 2% alginate, which
was then gelled by mixing with calcium sulfate. The gel was injected subcutaneously on the
dorsal side of the experimental animals. Histological examination of the implants revealed
signs of endochondrosis with woven bone deposition. The equilibrium modulus of the newly
formed bone increased with time up to 678 kPa at 30 weeks, as determined by biomechanical
analysis. This value is approximately 1.62% of native bovine cancellous bone. In another study
[53] of large mandibular bone defect repair, dog MSCs cultured with ß-TCP to generate
osteogenic cells were co-implanted with a titanium plate into a 30 mm segmental mandible
defect. Biomechanical tests showed a significant difference between the experimental group
(with cells) and the control group (without cells), highlighting the importance of the MSCs in
bone formation. Pedicled bone flaps based on collagen I scaffolds, bone marrow stromal cells
and a PTFE membrane have been successfully generated using the carotid artery and jugular
vein or the saphenous bundle as a vascular axis in a mouse model [54]. The osteogenetic
stimulus was supplied by the injection of mouse MSCs cultured in osteogenic medium inside
the space delimited by the PTFE membrane. After only 4 weeks islands of bone tissue were
present inside the membrane.
3.2. Clinical trials for bone engineering with mesenchymal stem cells
There is some clinical experience with bone reconstruction using expanded MSCs combined
with scaffolds. Constructs of expanded autologous MSCs in macroporous hydroxyapatite
were used in three patients with large segmental bone defects [55, 56].
Warnke and Terheyden have developed a two stage procedure for mandible reconstruction
in humans [57]. This study used prefabrication in the latissimus dorsi muscle with the aim of
reconstructing a 70 mm defect in the mandible of a man who underwent a tumor resection
years previously. The entire construction of the mandible was built using blocks of Bio-Oss®
and MSCs that had been cultured in the presence of BMP-7. The Bio-Oss® and MSCs were
placed in a titanium cage, and implanted into the latissimus dorsi of the patient and maintained
in situ for 7 weeks. Subsequently, this unit, together with the vascular bundle that supplied it,
was removed and re-implanted in the mandible defect by fixation with titanium plates and
microvascular sutures connecting the vasculature to the external carotid artery and the
cephalic vein.
4. Adipose-derived stem cells for oral and maxillofacial tissue engineering
4.1. Characterization of adipose-derived stem cells
There is a general consensus that SVF cells are a heterogeneous population, and no specific
ranges for each subpopulation have been agreed upon formally [21]. In contrast, the Interna‐
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tional Society for Cell Therapy has provided guidelines for the definition of MSCs, as follows.
(1) MSCs must be plastic-adherent when maintained in standard culture conditions. (2) MSCs
must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b,
CD79α or CD19 and HLA-DR surface antigens. (3) MSCs must differentiate into osteoblasts,
adipocytes and chondroblasts in vitro [58].
SVF cells include preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells
(ECs), resident monocytes/macrophages, lymphocytes and ASCs [59]. Although the criteria to
define SVF cells remain in contention, the heterogeneous SVF cell population includes putative
ASCs (CD31-, CD34+/-, CD45-, CD90+, CD105-, CD146-), endothelial (progenitor) cells (CD31+,
CD34+, CD45-, CD90+, CD105-, CD146+), vascular smooth muscle cells or pericytes (CD31-,
CD34+/-, CD45-, CD90+, CD105-, CD146+), and hematopoietic cells (CD45+) in uncultured
conditions [60]. Cultured ASCs show an extensive proliferative ability in an uncommitted state
while retaining their multilineage differentiation potential. ASCs express the mesenchymal
stem cell markers CD10, CD13, CD29, CD34, CD44, CD54, CD71, CD90, CD105, CD106, CD117,
CD166 and STRO-1. They are negative for the hematopoietic lineage markers CD45, CD14,
CD16, CD56, CD61, CD62E, CD104, and CD106 and for the EC markers CD31, CD144, and von
Willebrand factor [20, 61, 62]. Morphologically, cultured ASCs are fibroblast-like and preserve
their shape after expansion in vitro [20, 63]. The ASC specific surface markers CD29, CD90,
and CD166 increase during culture [64]. In later passages, ASC cultures are homogeneous and
exhibit fibroblastoid morphology. The composition of the subpopulations, therefore, may
change during expansion [65, 66]. Therefore ASCs match the standard criteria for MSCs.
4.2. Differentiation potential of osteogenic cells in vitro and in vivo
Numerous studies have presented results that clearly show that ASCs can differentiate into
osteoblasts [20, 59, 63, 67, 68]. ASCs exhibit a time-dependent expression of genes and proteins
associated with the osteoblast phenotype, including ALP, Type I Collagen, OPN, ON, RUNX2,
BMP-2, BMP-4 and BMP receptors I and II [20, 67, 69, 70]. Additionally, between 2 and 4 weeks
of culture, mineralization of the extracellular matrix begins and proceeds via the activity of
ALP, an enzyme that hydrolyzes phosphate esters making available inorganic phosphate to
form hydroxyapatite [19, 20, 71].
Furthermore, recent reports have shown that ASCs co-cultured with ECs exhibit enhanced
osteogenesis [72, 73]. ASCs exhibited increased secretion of alkaline phosphatase and osteo‐
calcin, and an overall increase in osteogenesis in the co-cultured situation compare with other
experimental groups. These interactions may be important to regenerate bone in large bone
defects since angiogenesis plays a key role in regeneration of large amounts of tissue.
4.3. Fabricated bone engineering with adipose-derived stem cells
To make a functional prefabricated bone, three elements are required: scaffolds to provide a
three-dimensional support, growth factors to stimulate neovascularization, and MSCs to give
an osteoinductive stimulus. Okuda et al. have reported prefabrication of tissue engineered
bone grafts using ASCs in a rat model [74]. ASCs and porous β-TCP as scaffold material were
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implanted into the superficial inferior epigastric artery flap. After prefabrication for eight
weeks, the prefabricated flaps were elevated and the pedicles were clamped for 4 h; prefabri‐
cated tissue was harvested two weeks later. The osteogenic capacity of the prefabricated graft
was not significantly different from non-prefabricated grafts examined after two weeks in a
rat model. Furthermore, an analysis of angiogenesis suggested that the prefabricated model
possessed significantly greater capillary density than the non-prefabricated model.
Recently, repair of a large bony defect using ASCs was clinically reported [75-77] (Table. 1).
Mesima°ki and colleagues published a clinical case report of prefabricated bone tissue
engineering [77]. The large bony defect was reconstructed with a microvascular flap using
autologous ASCs, β-TCP and BMP-2, 36 months after a hemimaxillectomy due to a large
keratocyst. After expansion of ASCs and cultivation with β-TCP and BMP-2 in vitro, a titanium
cage filled with ASCs and β-TCP was inserted through a vertical incision into a pouch prepared
in the patient’s left rectus abdominis muscle. The rectus abdominis free flap was raised. Before
severing the vascular supply to the muscle, the muscle pouch was carefully opened and the
titanium cage was opened. After severing the vessels, the flap was placed in the maxillary
defect; the inferior epigastric artery was anastomosed end-to-end to the facial artery and the
vein end-to-end to the facial vein.
Clinical reports/trials with
ASCs
Design Results Ref
Widespread calvarial defect Autologous SVFs with fibrin
glue
Success, follow-up: 3 months
after operation
[75]
Large calvarial defect Implant autologous cultured
ASCs with β-TCP
No complications, follow-up: 3
months after operations
[76]
Maxillary reconstruction Fabricated bone tissue using
autologous cultured ASCs with
β-TCP and BMP-2
Success, follow-up: 8 months
after operations
[77]
Large osseous defect Autologous ASCs with different
scaffolds
Recruiting NCT01218945
*
Avascular Necrosis of the
Femoral Head
Autologous adipose tissue
derived MSCs transplantation
Phase 1, 2 NCT01532076
*
Abbreviations: SVF; Stromal Vascular Fraction, ASCs; Adipose-derived Stem Cells, β-TCP; Beta-tricalcium phosphate,
MSCs; mesenchymal stem cells, BMP; bone morphogenetic protein
(*Identifier on Clinical trials website: *http://clinicaltrials.gov/ct2/results?term=adipose+derived+cells+bone).
Table 1. Clinical reports/trials for large bony defect using adipose-derived stem cells
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5. Future perspective
In the past decade, basic research characterizing ASCs shows that these cells have the potential
to regenerate tissue defects such as large bone defects, and clinical studies have examined the
potential use of ASCs to reconstruct oral and maxillofacial tissue. Although clinical studies
have only just begun, the use of ASCs in the clinical setting is extremely promising because
ASCs are a readily available, multipotent, and abundant cell type with the capability to
undergo robust osteogenesis. However, further studies, including research to determine the
mechanism of osteogenic differentiation and studies to evaluate the safety of ASC usage, will
be necessary to realize the potential of ASCs in clinical regenerative medicine of the future.
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